bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Authors: Weide Benjamin , Martens Alexander , Hassel Jessica C. , Berking Carola , Postow Michael A. , Bisschop Kees , Simeone Ester , Mangana Johanna , Schilling Bastian , Di Giacomo Anna Maria , Brenner Nicole , Kähler Katharina , Heinzerling Lucie , Gutzmer Ralf , Bender Armin , Gebhardt Christoffer , Romano Emanuela , Meier Friedegund , Martus Peter , Maio Michele , Blank Christian , Schadendorf Dirk , Dummer Reinhard , Ascierto Paolo A. , Hospers Geke , Garbe Claus , Wolchok Jedd D.
Published: April 2023

Overall survival (OS) following pembrolizumab according to the count of favorable baseline factors considering death from any reason as "event". In total, 194 patients with complete data of the four baseline markers as considered in the combination model died during follow up. The reasons of death were progressive melanoma (n=189), voluntary physician-assisted ending of life (n=2), or cerebral insult (n=3). In contrast to all other analyses throughout the manuscript, Kaplan-Meier curves of OS according to the number of favorable baseline factors are presented considering death from any reason as "event". The discriminatory ability was marginally higher compared to the analysis of melanoma-specific OS (c-index 0.783 vs. 0.782), and differences in OS remained significant in all pairwise comparisons between the five categories (log rank p=0.046 regarding the difference between patients with 4 or 3 favorable factors, p=0.009 regarding the difference between patients with 1 and 0 favorable factors, p<0.001 for all other comparisons). Censoring is indicated by vertical lines.
Supplementary Figure 1 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Authors: Weide Benjamin , Martens Alexander , Hassel Jessica C. , Berking Carola , Postow Michael A. , Bisschop Kees , Simeone Ester , Mangana Johanna , Schilling Bastian , Di Giacomo Anna Maria , Brenner Nicole , Kähler Katharina , Heinzerling Lucie , Gutzmer Ralf , Bender Armin , Gebhardt Christoffer , Romano Emanuela , Meier Friedegund , Martus Peter , Maio Michele , Blank Christian , Schadendorf Dirk , Dummer Reinhard , Ascierto Paolo A. , Hospers Geke , Garbe Claus , Wolchok Jedd D.
Published: April 2023

Overall survival (OS) according to the combination model in the combined discovery/confirmation cohort and the validation cohort. Four baseline factors had independent prognostic impact (LDH, pattern of distant metastases, relative lymphocyte counts and relative eosinophil counts) according to Cox regression analysis of the combined discovery/confirmation cohort. Considering those 4 independent factors, large differences in OS were observed between groups of patients defined by the number of favorable pre-treatment factors. Kaplan-Meier curves for overall survival are presented according to the combination model for 346 patients with complete data of the combined discovery/confirmation cohort (A). All 4 single factors as considered in the combination model were again associated with OS and had independent impact in 166 patients of the validation cohort with complete data. Differences in OS were all significant (P<0.05) in comparisons between patients with different numbers of favorable baseline markers (B) except the difference between patients with 0 vs 1 favorable factors (P=0.975).
Supplementary Figure S1: 13 mutational signatures from Mutational Signatures in Breast Cancer: The Problem at the DNA Level
Authors: Nik-Zainal Serena , Morganella Sandro
Published: April 2023

Supplementary Figure S1: 13 signatures
Supplementary Methods, Supplementary Figures 1-8, Supplementary Tables 1-5, Supplementary References from A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients
Authors: Yang Lingjian , Taylor Janet , Eustace Amanda , Irlam Joely J. , Denley Helen , Hoskin Peter J. , Alsner Jan , Buffa Francesca M. , Harris Adrian L. , Choudhury Ananya , West Catharine M.L.
Published: April 2023

Table S1. Clinicopathologic details compared to original trial; Table S2. FFPE sample details by randomisation arm; Table S3 Predictive significance of the literature signatures for LPFS analysis; Table S4 Bladder cancer-specific hypoxia signature genes; Table S5. Distribution of clinicopathological factors by hypoxia signature scores; Figure S1. BCON consort diagram; Figure S2. Bladder cancer-specific hypoxia gene co-expression network; Figure S3. Fixed effect meta-analysis of the hazard ratios of the 24-gene hypoxia signature developed in this work on 6 independent cohorts; Figure S4. Distribution of 24-gene hypoxia signature score in tumours with high or low protein expressions; Figure S5. Kaplan-Meier plot for BCON patients receiving radiotherapy only; Figure S6. Kaplan-Meier plot for BCON patients having high 24-gene hypoxia signature scores and high Riester risk signature scores; Figure S7. Kaplan-Meier plot for BCON patients receiving radiotherapy only; Supplementary Figure S8. Kaplan-Meier plot for BCON patients having high 24-gene hypoxia signature scores and high Lendahl risk signature scores.
Supplementary Figure 2 from Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition
Authors: Sanmartín Elena , Muñoz Lisandra , Piqueras Marta , Sirerol J. Antoni , Berlanga Pablo , Cañete Adela , Castel Victoria , Font de Mora Jaime
Published: April 2023

Chromotripsis in 11qdel neuroblastoma patients. A, molecular karyotype reveals chromothripsis (at least 28 consecutive segmental breaks identified by changes in the Weighted Log2 Ratio coinciding with changes in the profile of Allele Peaks) on chromosome 5 in neuroblastoma TI_423 and one segmental break in neuroblastoma NBX_19. B, molecular karyotype reveals chromothripsis (at least 13 consecutive segmental breaks identified by changes in the Weighted Log2 Ratio coinciding with changes in the profile of Allele Peaks) on chromosome 17 in neuroblastoma NBX_19 and two segmental breaks in neuroblastoma TI_423.
Supplementary Figure 6 from Personalized Medicine–Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids
Authors: Raghavan Shreya , Mehta Pooja , Ward Maria R. , Bregenzer Michael E. , Fleck Elyse M. A. , Tan Lijun , McLean Karen , Buckanovich Ronald J. , Mehta Geeta
Published: April 2023

Supplementary Figure 6: Histology of tumor initiation xenografts from Pt259 OvCSC spheroids
Supplemental R File 3-NCI TMA from Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Authors: Hunt Kelly K. , Karakas Cansu , Ha Min Jin , Biernacka Anna , Yi Min , Sahin Aysegul A. , Adjapong Opoku , Hortobagyi Gabriel N. , Bondy Melissa L. , Thompson Patricia A. , Cheung Kwok Leung , Ellis Ian O. , Bacus Sarah , Symmans W. Fraser , Do Kim-Anh , Keyomarsi Khandan
Published: April 2023

R File codes pertaining to NCI cohort
Supplementary Figure 4 from Personalized Medicine–Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids
Authors: Raghavan Shreya , Mehta Pooja , Ward Maria R. , Bregenzer Michael E. , Fleck Elyse M. A. , Tan Lijun , McLean Karen , Buckanovich Ronald J. , Mehta Geeta
Published: April 2023

Supplementary Figure 4: Immunohistochemistry of primary patient ascites and OvCSC spheroid tumor xenografts
Supplemental Figure Legends from Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Authors: Hunt Kelly K. , Karakas Cansu , Ha Min Jin , Biernacka Anna , Yi Min , Sahin Aysegul A. , Adjapong Opoku , Hortobagyi Gabriel N. , Bondy Melissa L. , Thompson Patricia A. , Cheung Kwok Leung , Ellis Ian O. , Bacus Sarah , Symmans W. Fraser , Do Kim-Anh , Keyomarsi Khandan
Published: April 2023

Figure legends pertaining to supplemental figures 1-3
Supplementary Figure 3 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Authors: Krejcik Jakub , Frerichs Kris A. , Nijhof Inger S. , van Kessel Berris , van Velzen Jeroen F. , Bloem Andries C. , Broekmans Marloes E.C. , Zweegman Sonja , van Meerloo Johan , Musters René J.P. , Poddighe Pino J. , Groen Richard W.J. , Chiu Christopher , Plesner Torben , Lokhorst Henk M. , Sasser A. Kate , Mutis Tuna , van de Donk Niels W.C.J.
Published: April 2023

Daratumumab-mediated CD38 reduction on NK cells is abrogated by depleting monocytes from PBMCs.
Supplementary Figure 1 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Authors: Krejcik Jakub , Frerichs Kris A. , Nijhof Inger S. , van Kessel Berris , van Velzen Jeroen F. , Bloem Andries C. , Broekmans Marloes E.C. , Zweegman Sonja , van Meerloo Johan , Musters René J.P. , Poddighe Pino J. , Groen Richard W.J. , Chiu Christopher , Plesner Torben , Lokhorst Henk M. , Sasser A. Kate , Mutis Tuna , van de Donk Niels W.C.J.
Published: April 2023

Loss of CD38 from the MM cell membrane is associated with reduced CDC and ADCC
Supplemental Table 1 from Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen
Authors: Brechbuhl Heather M. , Finlay-Schultz Jessica , Yamamoto Tomomi M. , Gillen Austin E. , Cittelly Diana M. , Tan Aik-Choon , Sams Sharon B. , Pillai Manoj M. , Elias Anthony D. , Robinson William A. , Sartorius Carol A. , Kabos Peter
Published: April 2023

Expression of genes associated with activated fibroblasts.
Supplemental Figures from Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen
Authors: Brechbuhl Heather M. , Finlay-Schultz Jessica , Yamamoto Tomomi M. , Gillen Austin E. , Cittelly Diana M. , Tan Aik-Choon , Sams Sharon B. , Pillai Manoj M. , Elias Anthony D. , Robinson William A. , Sartorius Carol A. , Kabos Peter
Published: April 2023

SFig. 1: Cellular morphology defines tumor cell from stroma.; SFig. 2: Primary derived stroma from cancer-associated and normal breast tissue is highly enriched for fibroblasts.; SFig 3: Immortalized primary derived fibroblasts express high levels of vimentin and FSP1.; SFig. 4: Primary derived cancer fibroblasts are highly similar to normal bone marrow-derived fibroblasts.; SFig. 5: Influence from CD146neg fibroblasts on ER+ breast cancer cells reduces ER expression and estrogen dependency.; SFig 6. Influence from CD146neg fibroblasts on ER+ breast cancer is predictive of decreased recurrence-free survival.
Supplementary Tables S4-S6 from The Genomic Landscape of Male Breast Cancers
Authors: Piscuoglio Salvatore , Ng Charlotte K.Y. , Murray Melissa P. , Guerini-Rocco Elena , Martelotto Luciano G. , Geyer Felipe C. , Bidard Francois-Clement , Berman Samuel , Fusco Nicola , Sakr Rita A. , Eberle Carey A. , De Mattos-Arruda Leticia , Macedo Gabriel S. , Akram Muzaffar , Baslan Timour , Hicks James B. , King Tari A. , Brogi Edi , Norton Larry , Weigelt Britta , Hudis Clifford A. , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S4: Somatic single nucleotide variants (SNVs) and insertion/deletions (indels). Supplementary Table S5: Frequencies of mutations found in ER-positive/HER2-negative male breast cancer vs subsets of female breast cancer from the TCGA study. Supplementary Table S6: MutSigCV analysis of significantly mutated genes in MaBCs.
Supplementary Methods from The Genomic Landscape of Male Breast Cancers
Authors: Piscuoglio Salvatore , Ng Charlotte K.Y. , Murray Melissa P. , Guerini-Rocco Elena , Martelotto Luciano G. , Geyer Felipe C. , Bidard Francois-Clement , Berman Samuel , Fusco Nicola , Sakr Rita A. , Eberle Carey A. , De Mattos-Arruda Leticia , Macedo Gabriel S. , Akram Muzaffar , Baslan Timour , Hicks James B. , King Tari A. , Brogi Edi , Norton Larry , Weigelt Britta , Hudis Clifford A. , Reis-Filho Jorge S.
Published: April 2023

Supplementary Methods detailing the methods employed for Copy number alteration (CNA) analysis, Sanger sequencing and supplementary references.
Supplementary Figures S4 and S5 from The Genomic Landscape of Male Breast Cancers
Authors: Piscuoglio Salvatore , Ng Charlotte K.Y. , Murray Melissa P. , Guerini-Rocco Elena , Martelotto Luciano G. , Geyer Felipe C. , Bidard Francois-Clement , Berman Samuel , Fusco Nicola , Sakr Rita A. , Eberle Carey A. , De Mattos-Arruda Leticia , Macedo Gabriel S. , Akram Muzaffar , Baslan Timour , Hicks James B. , King Tari A. , Brogi Edi , Norton Larry , Weigelt Britta , Hudis Clifford A. , Reis-Filho Jorge S.
Published: April 2023

Supplementary Figure S4: Morphologic and immunophenotypic features of case MB-T88. Supplementary Figure S5: GATA3 mutational spectrum in male breast cancer and female breast cancer and the impact of selected mutations on the survival of male breast cancer patients.
Supplemental Table 4 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Authors: Wang Xiuli , Walter Miriam , Urak Ryan , Weng Lihong , Huynh Christian , Lim Laura , Wong ChingLam W. , Chang Wen-Chung , Thomas Sandra H. , Sanchez James F. , Yang Lu , Brown Christine E. , Pichiorri Flavia , Htut Myo , Krishnan Amrita Y. , Forman Stephen J.
Published: April 2023

DAVID Functional annotation analysis
Supplemental Table 3 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Authors: Wang Xiuli , Walter Miriam , Urak Ryan , Weng Lihong , Huynh Christian , Lim Laura , Wong ChingLam W. , Chang Wen-Chung , Thomas Sandra H. , Sanchez James F. , Yang Lu , Brown Christine E. , Pichiorri Flavia , Htut Myo , Krishnan Amrita Y. , Forman Stephen J.
Published: April 2023

Down-regulated genes
Figure S2 from Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Authors: Li Si , Siriwon Natnaree , Zhang Xiaoyang , Yang Shuai , Jin Tao , He Feng , Kim Yu Jeong , Mac John , Lu Zhengfei , Wang Sijie , Han Xiaolu , Wang Pin
Published: April 2023

(A) The expression of PD-L1 on H292-CD19 and SKOV3-CD19 was determined by flow cytometry. (B) Both CAR19 and CAR19.Î±PD1 T cells were cocultured with SKOV3-CD19 cells for different durations. IFN-Î³ production was measured by ELISA (n=5, mean {plus minus} SEM; ns, not significant, P > 0.05; *P < 0.05). (C) CAR19 T cells with or without anti-PD-1 (0.6 Âµg/ml), and CAR19.Î±PD1 T cells were cocultured with H292-CD19 cells for 24 or 72 hours. IFN-Î³ production was measured by ELISA (n=4, mean {plus minus} SEM; ns, not significant, P > 0.05; ***P < 0.001)
Supplementary Methods, Supplementary Figures 1-2, Supplementary Tables 1-4 from Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma
Authors: Ying Zhang Xiao , Jin Meiyan , Peterson Luke F. , Bernard Denzil , Saiya-Cork Kamlai , Yildiz Mehmet , Wang Shaomeng , Kaminski Mark S. , Chang Alfred E. , Klionsky Daniel J. , Malek Sami N.
Published: April 2023

Table S1. Yeast strains; Table S2. Primers used for yeasts mutagenesis; Table S3: B-factor for GTP/GDP during MD simulations with WT RRAGC or with point Mutations; Table S4: Energy contribution of each residue (kcal/mol) to GTP and GDP binding; Figure S1A: MD simulations of RRAGC (A)WT and (B-J) individual point mutations in complex with GDP (shown as sticks); Figure S1B: MD simulations of RRAGC (A)WT and (B-J) individual point mutations in complex with GTP (shown as sticks); Supplementary Figure S2: HA-Raptor immunoprecipitation out of transiently transfected HEK293T cells.
Supplementary Figures from ADNP Is a Therapeutically Inducible Repressor of WNT Signaling in Colorectal Cancer
Authors: Blaj Cristina , Bringmann Agnes , Schmidt Eva Marina , Urbischek Manuela , Lamprecht Sebastian , Fröhlich Thomas , Arnold Georg J. , Krebs Stefan , Blum Helmut , Hermeking Heiko , Jung Andreas , Kirchner Thomas , Horst David
Published: April 2023

Suppl. Figure 1. (A) Immunostaining for ADNP and ÃŽÂ²-Catenin on serial sections of two colon cancers. (B) Staining intensities of ADNP in colon cancer cells (n = 500, 5 different tumors) with high or low nuclear ÃŽÂ²- Catenin expression. P value is t test result. (C) Immunostaining for ADNP in normal mucosa. Right panels aremagnifications of areas boxed in left panel.Scale bars, 100 ÃŽÂ¼m. Suppl. Figure 2. (A-B) Immunoblotting of indicated proteins on whole cell lysates in ADNP wild-type (WT) or knockout (KO) cell lines. Numbers below immunoblots indicate fold change by densitometry. (C) Representative micrographs (left panels) and quantification (right panels) of migrated or invaded tumor cells in transwell assays for indicated ADNP WT and KO cell lines, treated with indicated siRNAs or control siRNA (siCtrl). (D) Representative proliferation kinetics based on cell quantification by impedance measurements. Data are mean, n {greater than or equal to} 3. ÃŽÂ²-Cat = ÃŽÂ²-Catenin. Suppl. Figure 3. Representative micrographs (left panels) and quantification (right panels) of migrated or invaded HCT116 or SW1222 tumor cells with transient ADNP overexpression by transfection with p4.2-hADNP compared to empty p4.2 vector for 24 h in transwell assays. Suppl. Figure 4. (A) Immunoblotting of indicated proteins on whole cell lysates of SW1222, HCT116 and primary (P-Tu) colon cancer cells. Numbers below immunoblots indicate fold change by densitometry. (B) Immunostaining of SW1222, HCT116 and primary colon cancer (P-Tu) xenografts for ÃŽÂ²-Catenin. Scale bars, 50 ÃŽÂ¼m. Suppl. Figure 5. (A-B) Dual-luciferase assays for indicatedADNPwild-type (WT) or knockout (KO) colon cancer cells transfected with TOPflash reporter constructs. Treatments with PBS, ketamine or the WNT inhibitor XAV939, as indicated. (C) Representativemicrographs (left panels) and quantification (right panels) ofmigrated or invaded HCT116 or SW1222 tumor cells in transwell assays, treated with PBS or 100 ÃŽÂ¼M ketamine for 24 h, as indicated.Data aremean {plus minus}SD, Pvalues are t test results, n {greater than or equal to} 3. Suppl. Figure 6. Assessment of nuclear ÃŽÂ²-catenin staining in primary human colorectal cancers. Tumors were assigned scores from 0 (no nuclear ÃŽÂ²-catenin) to 3 (most tumor cells with strong nuclear ÃŽÂ²-catenin) and accordingly categorized as ÃŽÂ²-catenin low (score 0-1) and ÃŽÂ²-catenin high (score 2-3). Scale bars, 100 ÃŽÂ¼m.
Supplementary Figure S4 from Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia
Authors: Jin Bei , Wang Chengyan , Li Juan , Du Xin , Ding Ke , Pan Jingxuan
Published: April 2023

p-Niclosamide reduces survival and self-renewal of leukemia stem cells in CML mice.
Supplementary Tables from Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
Authors: Beltran Himisha , Wyatt Alexander W. , Chedgy Edmund C. , Donoghue Adam , Annala Matti , Warner Evan W. , Beja Kevin , Sigouros Michael , Mo Fan , Fazli Ladan , Collins Colin C. , Eastham James , Morris Michael , Taplin Mary-Ellen , Sboner Andrea , Halabi Susan , Gleave Martin E.
Published: April 2023

Table S1: Targeted gene panel for DNA sequencing Table S2: List of genes in the custom Nanostring gene panel Table S3: Clinical characteristics of the patient cohort. Table S4: Predicted minimum tumor cellularity estimated by targeted DNA sequencing. Table S5: Somatic mutation calls from targeted DNA-sequencing. Table S6: Germline mutation calls from targeted DNA sequencing. Table S7: Comparison of non-silent mutations detected by targeted sequencing and whole exome sequencing (WES). Table S8: Differential gene expression between treated and untreated specimens Table S9: Gene expression values (normalized counts) of radical prostatectomy specimens Table S10: Gene expression values (normalized counts) of tumor biopsies Table S11: Gene expression values (normalized counts) of benign prostate specimens
Supplementary Information from Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
Authors: Beltran Himisha , Wyatt Alexander W. , Chedgy Edmund C. , Donoghue Adam , Annala Matti , Warner Evan W. , Beja Kevin , Sigouros Michael , Mo Fan , Fazli Ladan , Collins Colin C. , Eastham James , Morris Michael , Taplin Mary-Ellen , Sboner Andrea , Halabi Susan , Gleave Martin E.
Published: April 2023

Supplementary Methods, Figures, Table Legends Supplementary Figure 1: Representative Hematoxylin and Eosin stained photomicrographs of prostatectomy specimens demonstrating the effects of neoadjuvant chemohormonal therapy. Supplementary Figure 2: Quality metrics for targeted DNA sequencing of FFPE biopsy and RP specimens. Supplementary Figure 3: Somatic mutations detected pre- and post-treatment through targeted DNA sequencing. Supplementary Figure 4: Differences in the number and allelic frequency of somatic mutations between treated and untreated specimens. Supplementary Figure 5: Persistence of TP53 mutations in post-treated radical prostatectomy (RP) specimens. Supplementary Figure 6: Representative copy number plots from targeted sequencing of diagnostic biopsies and RP specimens from the untreated arm. Supplementary Figure 7: Pearson's correlation comparing the Nanostring platform (x axis) and RNA-seq (y axis) performed in 13 matched cases. Supplementary Figure 8: Scatterplots showing Pearson correlation between Nanostring data obtained from matched FFPE and fresh/frozen tissue in 7 patients. Supplementary Figure 9: Gene expression of PTEN (y axis) relative to genomic status (PTEN deletion or wild type (WT). Supplementary Figure 10: Left: Correlation of TMPRSS2-ERG fusion transcript expression (x axis) and ERG gene expression (y axis). Right: ERG expression vs. TMPRSS2-ERG fusion status with positive defined as normalized count> 50. Supplementary Figure 11: Principal component analysis plotted using the Biological Coefficient of Variation (BCV) distance as part of the edgeR package. Supplementary Figure 12: Unsupervised analysis of expression of all genes within the panel in radical prostatectomies from treated (green) and untreated (yellow) arms. Red= high expression; blue= low expression.
Figure S2 from Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics
Authors: Yan Yuanqing , Gao Ruli , Trinh Thao L.P. , Grant Maria B.
Published: April 2023

Figure S2 shows the expression levels of PD-1, CTLA4, CXCL12 and IDO in PANC-1 cell line
Supplementary Data from Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO)
Authors: Acerbi Francesco , Broggi Morgan , Schebesch Karl-Michael , Höhne Julius , Cavallo Claudio , De Laurentis Camilla , Eoli Marica , Anghileri Elena , Servida Maura , Boffano Carlo , Pollo Bianca , Schiariti Marco , Visintini Sergio , Montomoli Cristina , Bosio Lorenzo , La Corte Emanuele , Broggi Giovanni , Brawanski Alexander , Ferroli Paolo
Published: April 2023

Supplementary Material. Serious Adverse Events reported for the 56 initially enrolled patients in the FLUOGLIO study.
Supplementary Figures 1-8, Supplementary Tables 1-3 from BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma
Authors: Niessner Heike , Sinnberg Tobias , Kosnopfel Corinna , Smalley Keiran S.M. , Beck Daniela , Praetorius Christian , Mai Marion , Beissert Stefan , Kulms Dagmar , Schaller Martin , Garbe Claus , Flaherty Keith T. , Westphal Dana , Wanke Ines , Meier Friedegund
Published: April 2023

Suppl. Figure 1 Encorafenib combined with binimetinib leads to increased growth inhibition and increased induction of apoptosis in NRAS-mutant melanoma cells Suppl. Figure 2 The panRAF inhibitor Raf265 combined with binimetinib leads to growth inhibition, induction of apoptosis and ER stress genes in NRAS-mutant melanoma cells Suppl. Figure 3 Dabrafenib combined with trametinib leads to strong growth inhibition, induction of apoptosis and ER stress genes in NRAS-mutant melanoma cells Suppl. Figure 4 In normal skin cells encorafenib and binimetinib induce only weak growth inhibition and no significant levels of apoptosis Suppl. Figure 5 BRAFi combined with MEKi leads to an ER stress response involving the PERK pathway? Suppl. Figure 6 BRAFi combined with MEKi leads to activation of PUMA in patient-derived tumor slice cultures. Suppl. Figure 7 Binimetinib and encorafenib induced apoptosis is partly mediated by the anti-apoptotic BCL-2 family members and by the pro-apoptotic BH3-only protein NOXA . Suppl. Figure 8 NRAS mutated cells resistant to encorafenib, binimetinib or the combination of encorafenib and binimetinib.
Supplemental figure legends from Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Authors: Berns Katrien , Sonnenblick Amir , Gennissen Annemiek , Brohée Sylvain , Hijmans E. Marielle , Evers Bastiaan , Fumagalli Debora , Desmedt Christine , Loibl Sibylle , Denkert Carsten , Neven Patrick , Guo Wei , Zhang Fan , Knijnenburg Theo A. , Bosse Tjalling , van der Heijden Michiel S. , Hindriksen Sanne , Nijkamp Wouter , Wessels Lodewyk F.A. , Joensuu Heikki , Mills Gordon B. , Beijersbergen Roderick L. , Sotiriou Christos , Bernards René
Published: April 2023

Supplemental Legends for figures S1-S5
Supplemental Table S2 and Table S3 from Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Authors: Berns Katrien , Sonnenblick Amir , Gennissen Annemiek , Brohée Sylvain , Hijmans E. Marielle , Evers Bastiaan , Fumagalli Debora , Desmedt Christine , Loibl Sibylle , Denkert Carsten , Neven Patrick , Guo Wei , Zhang Fan , Knijnenburg Theo A. , Bosse Tjalling , van der Heijden Michiel S. , Hindriksen Sanne , Nijkamp Wouter , Wessels Lodewyk F.A. , Joensuu Heikki , Mills Gordon B. , Beijersbergen Roderick L. , Sotiriou Christos , Bernards René
Published: April 2023

Supplemental Table S2: Patient characteristics FinHer Supplemental Table S3: Patient characteristics Responsify
Figure S1 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification
Authors: Seed George , Yuan Wei , Mateo Joaquin , Carreira Suzanne , Bertan Claudia , Lambros Maryou , Boysen Gunther , Ferraldeschi Roberta , Miranda Susana , Figueiredo Ines , Riisnaes Ruth , Crespo Mateus , Rodrigues Daniel Nava , Talevich Eric , Robinson Dan R. , Kunju Lakshmi P. , Wu Yi-Mi , Lonigro Robert , Sandhu Shahneen , Chinnaiyan Arul M. , de Bono Johann S.
Published: April 2023

Plotting a) the median spread of coverage per-gene, from the pooled reference data and b) the per-gene standard deviations for duplicated samples shows that some genes are less reliable than others.
Table S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Authors: Pierobon Mariaelena , Ramos Corinne , Wong Shukmei , Hodge K. Alex , Aldrich Jessica , Byron Sara , Anthony Stephen P. , Robert Nicholas J. , Northfelt Donald W. , Jahanzeb Mohammad , Vocila Linda , Wulfkuhle Julia , Gambara Guido , Gallagher Rosa I. , Dunetz Bryant , Hoke Nicholas , Dong Ting , Craig David W. , Cristofanilli Massimo , Leyland-Jones Brian , Liotta Lance A. , O'Shaughnessy Joyce A. , Carpten John D. , Petricoin Emanuel F.
Published: April 2023

Tumor percentage for specimens undergoing exome sequencing.
Figure S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Authors: Pierobon Mariaelena , Ramos Corinne , Wong Shukmei , Hodge K. Alex , Aldrich Jessica , Byron Sara , Anthony Stephen P. , Robert Nicholas J. , Northfelt Donald W. , Jahanzeb Mohammad , Vocila Linda , Wulfkuhle Julia , Gambara Guido , Gallagher Rosa I. , Dunetz Bryant , Hoke Nicholas , Dong Ting , Craig David W. , Cristofanilli Massimo , Leyland-Jones Brian , Liotta Lance A. , O'Shaughnessy Joyce A. , Carpten John D. , Petricoin Emanuel F.
Published: April 2023

Pathway diagram of genes/proteins that were measured for this analyses and found altered across the 32 breast cancer metastases evaluated of the discovery set.
Supplement 1 from Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Authors: Brabander Tessa , van der Zwan Wouter A. , Teunissen Jaap J.M. , Kam Boen L.R. , Feelders Richard A. , de Herder Wouter W. , van Eijck Casper H.J. , Franssen Gaston J.H. , Krenning Eric P. , Kwekkeboom Dik J.
Published: April 2023

Supplement Table 1. A. Characteristics of the 4 patients with acute leukemia in follow-up
Supplementary legend from Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase
Authors: Dai Xiaoyang , Yan Juan , Fu Xuhong , Pan Qiuming , Sun Danni , Xu Yuan , Wang Jiang , Nie Litong , Tong Linjiang , Shen Aijun , Zheng Mingyue , Huang Min , Tan Minjia , Liu Hong , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

Supplementary legend
Supplementary Table listed in article from HMGA2–FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer
Authors: Dong Jiaqiang , Wang Rui , Ren Gui , Li Xiaowei , Wang Jingbo , Sun Yi , Liang Jie , Nie Yongzhan , Wu Kaichun , Feng Bin , Shang Yulong , Fan Daiming
Published: April 2023

Table S1 Primers for qRT-PCR; Table S2 Sequences of siRNAs for HMGA2, FOXL2, ITGA2 and E2F1; Table S3 HMGA2 in metastatic and non-metastatic GC; Table S4 FOXL2 in metastatic and non-metastatic GC; Table S5 ITGA2 in metastatic and non-metastatic GC; Table S6 Clinical significance of HMGA2, FOXL2 and ITGA2 in GC tissues
Figure S5 from HMGA2–FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer
Authors: Dong Jiaqiang , Wang Rui , Ren Gui , Li Xiaowei , Wang Jingbo , Sun Yi , Liang Jie , Nie Yongzhan , Wu Kaichun , Feng Bin , Shang Yulong , Fan Daiming
Published: April 2023

The expression levels of HMGA2, FOXL2 and ITGA2 are higher in lymph nodes and distant metastases than in primary cancer tissue samples. A. Statistical analysis of the staining intensities of HMGA2, FOXL2, ITGA2 in primary cancer tissue samples and lymph node metastases. B. The comparison of 3 types of GC cases according to the relative expression of 3 proteins between lymph node metastases and primary cancer tissue samples. C. Statistical analysis of the staining intensities of HMGA2, FOXL2, ITGA2 in primary cancer tissue samples and distant metastases. D. The comparison of 3 types of GC cases according to the relative expression of 3 proteins between distant metastases and primary cancer tissue samples.
Supplementary Table S4 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Authors: Choueiri Toni K. , Fishman Mayer N. , Escudier Bernard , McDermott David F. , Drake Charles G. , Kluger Harriet , Stadler Walter M. , Perez-Gracia Jose Luis , McNeel Douglas G. , Curti Brendan , Harrison Michael R. , Plimack Elizabeth R. , Appleman Leonard , Fong Lawrence , Albiges Laurence , Cohen Lewis , Young Tina C. , Chasalow Scott D. , Ross-Macdonald Petra , Srivastava Shivani , Jure-Kunkel Maria , Kurland John F. , Simon Jason S. , Sznol Mario
Published: April 2023

Genes from whole blood analysis with {greater than or equal to}1.2-fold differences between treatment groups over time. Twenty-four probesets identified from gene expression analysis.
Supplementary Table S3 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Authors: Choueiri Toni K. , Fishman Mayer N. , Escudier Bernard , McDermott David F. , Drake Charles G. , Kluger Harriet , Stadler Walter M. , Perez-Gracia Jose Luis , McNeel Douglas G. , Curti Brendan , Harrison Michael R. , Plimack Elizabeth R. , Appleman Leonard , Fong Lawrence , Albiges Laurence , Cohen Lewis , Young Tina C. , Chasalow Scott D. , Ross-Macdonald Petra , Srivastava Shivani , Jure-Kunkel Maria , Kurland John F. , Simon Jason S. , Sznol Mario
Published: April 2023

Genes from an analysis of tumor biopsies with {greater than or equal to}1.3-fold differences between treatment groups over time. Thirty-seven probesets identified from gene expression analysis.
Supplementary Table S2 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Authors: Choueiri Toni K. , Fishman Mayer N. , Escudier Bernard , McDermott David F. , Drake Charles G. , Kluger Harriet , Stadler Walter M. , Perez-Gracia Jose Luis , McNeel Douglas G. , Curti Brendan , Harrison Michael R. , Plimack Elizabeth R. , Appleman Leonard , Fong Lawrence , Albiges Laurence , Cohen Lewis , Young Tina C. , Chasalow Scott D. , Ross-Macdonald Petra , Srivastava Shivani , Jure-Kunkel Maria , Kurland John F. , Simon Jason S. , Sznol Mario
Published: April 2023

59 probesets from an analysis of blood These are probesets for which the null hypothesis was rejected and the change over time averaged over treatment groups was {greater than or equal to}1.2-fold.
Supplementary Table S1 from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Authors: Yam Clinton , Xu Xiaowei , Davies Michael A. , Gimotty Phyllis A. , Morrissette Jennifer J.D. , Tetzlaff Michael T. , Wani Khalida M. , Liu Shujing , Deng Wanleng , Buckley Meghan , Zhao Jianhua , Amaravadi Ravi K. , Haas Naomi B. , Kudchadkar Ragini R. , Pavlick Anna C. , Sosman Jeffrey A. , Tawbi Hussein , Walker Luke , Schuchter Lynn M. , Karakousis Giorgos C. , Gangadhar Tara C.
Published: April 2023

Supplementary Table S1. List of antibodies used in reverse phase protein array (RPPA). A table summarizing the antibodies used for RPPA in this study.
Supplementary Table S1 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Authors: Choueiri Toni K. , Fishman Mayer N. , Escudier Bernard , McDermott David F. , Drake Charles G. , Kluger Harriet , Stadler Walter M. , Perez-Gracia Jose Luis , McNeel Douglas G. , Curti Brendan , Harrison Michael R. , Plimack Elizabeth R. , Appleman Leonard , Fong Lawrence , Albiges Laurence , Cohen Lewis , Young Tina C. , Chasalow Scott D. , Ross-Macdonald Petra , Srivastava Shivani , Jure-Kunkel Maria , Kurland John F. , Simon Jason S. , Sznol Mario
Published: April 2023

108 probesets from an analysis of tumor biopsies These are probesets for which the null hypothesis was rejected and the change over time averaged over treatment groups was {greater than or equal to}1.3-fold.
Supplementary Information from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Authors: Choueiri Toni K. , Fishman Mayer N. , Escudier Bernard , McDermott David F. , Drake Charles G. , Kluger Harriet , Stadler Walter M. , Perez-Gracia Jose Luis , McNeel Douglas G. , Curti Brendan , Harrison Michael R. , Plimack Elizabeth R. , Appleman Leonard , Fong Lawrence , Albiges Laurence , Cohen Lewis , Young Tina C. , Chasalow Scott D. , Ross-Macdonald Petra , Srivastava Shivani , Jure-Kunkel Maria , Kurland John F. , Simon Jason S. , Sznol Mario
Published: April 2023

Supplementary Information
Supplementary Table 1 from Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma
Authors: Duffy Austin G. , Ma Chi , Ulahannan Susanna V. , Rahma Osama E. , Makarova-Rusher Oxana , Cao Liang , Yu Yunkai , Kleiner David E. , Trepel Jane , Lee Min-Jung , Tomita Yusuke , Steinberg Seth M. , Heller Theo , Turkbey Baris , Choyke Peter L. , Peer Cody J. , Figg William D. , Wood Brad J. , Greten Tim F.
Published: April 2023

Flow chart of dose level patient enrollment
Supplementary Figure S2 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Authors: Choueiri Toni K. , Fishman Mayer N. , Escudier Bernard , McDermott David F. , Drake Charles G. , Kluger Harriet , Stadler Walter M. , Perez-Gracia Jose Luis , McNeel Douglas G. , Curti Brendan , Harrison Michael R. , Plimack Elizabeth R. , Appleman Leonard , Fong Lawrence , Albiges Laurence , Cohen Lewis , Young Tina C. , Chasalow Scott D. , Ross-Macdonald Petra , Srivastava Shivani , Jure-Kunkel Maria , Kurland John F. , Simon Jason S. , Sznol Mario
Published: April 2023

Scatter-plot matrix of change from baseline (CFB) of CD3+, CD4+, and CD8+ cell percentages among the 36 patients. The diagonal panels give kernel density estimates and histograms summarizing the univariate distributions for the individual cell-type percentages.
Supplementary Figure 2 from Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma
Authors: Duffy Austin G. , Ma Chi , Ulahannan Susanna V. , Rahma Osama E. , Makarova-Rusher Oxana , Cao Liang , Yu Yunkai , Kleiner David E. , Trepel Jane , Lee Min-Jung , Tomita Yusuke , Steinberg Seth M. , Heller Theo , Turkbey Baris , Choyke Peter L. , Peer Cody J. , Figg William D. , Wood Brad J. , Greten Tim F.
Published: April 2023

Figure
Table S1 from The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages
Authors: Yeh Yu-Min , Hsu Shan-Ju , Lin Peng-Chan , Hsu Keng-Fu , Wu Pei-Ying , Su Wu-Chou , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

Clinical characteristics of colorectal cancer patients.
Supplementary Table 3 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Reverse Phase Protein Array (RPPA) data of either mouse T cells or human CD8+ Tumor Infiltrating Lymphocytes stimulated with anti-CD3 with or without HVEM-FC.
Movie 1 from The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages
Authors: Yeh Yu-Min , Hsu Shan-Ju , Lin Peng-Chan , Hsu Keng-Fu , Wu Pei-Ying , Su Wu-Chou , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

CSF-1R endocytosis in macrophage with CSF1R c.1085 A_A.
Supplementary Figure 5 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Detection of HVEM expression by flow cytometry in B16 OVA or B16 F10 cell lines.
Supplementary Figure 4 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Greatly attenuated recall response in OT-1 BTLA KO T cells in response to immunization with OVA peptide SIINFEKL.
Supplementary Figure 3 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Expression of BTLA in human CD8+ T cells according to differentiation status.
Figure S1 from The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages
Authors: Yeh Yu-Min , Hsu Shan-Ju , Lin Peng-Chan , Hsu Keng-Fu , Wu Pei-Ying , Su Wu-Chou , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

CSF1R c.1085A>G genetic variant in patients with different cancer types and different populations.
TableS1 from Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
Authors: Dalton Heather J. , Pradeep Sunila , McGuire Michael , Hailemichael Yared , MA Shaolin , Lyons Yasmin , Armaiz-Pena Guillermo N. , Previs Rebecca A. , Hansen Jean Marie , Rupaimoole Rajesha , Gonzalez-Villasana Vianey , Cho Min Soon , Wu Sherry Y. , Mangala Lingegowda S. , Jennings Nicholas B. , Hu Wei , Langley Robert , Mu Hong , Andreeff Michael , Bar-Eli Menashe , Overwijk Willem , Ram Prahlad , Lopez-Berestein Gabriel , Coleman Robert L. , Sood Anil K.
Published: April 2023

Table S1
Supplementary Figures 1-5, Supplementary Experimental Procedures, Supplementary References from Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
Authors: Dalton Heather J. , Pradeep Sunila , McGuire Michael , Hailemichael Yared , MA Shaolin , Lyons Yasmin , Armaiz-Pena Guillermo N. , Previs Rebecca A. , Hansen Jean Marie , Rupaimoole Rajesha , Gonzalez-Villasana Vianey , Cho Min Soon , Wu Sherry Y. , Mangala Lingegowda S. , Jennings Nicholas B. , Hu Wei , Langley Robert , Mu Hong , Andreeff Michael , Bar-Eli Menashe , Overwijk Willem , Ram Prahlad , Lopez-Berestein Gabriel , Coleman Robert L. , Sood Anil K.
Published: April 2023

S Figure 1 (A) C57BL/6 mice that received intra-peritoneal injections of IG10 cells were randomly assigned to one of two groups (control or B20 treatment). S Figure 2 (A) Bar graph represents the CD11b+/F4/80+ macrophages in tumor tissue by FACS analysis. S Figure 3 Anti-VEGF therapyÃ¢â,¬â€œresistant macrophages have heightened viability, migration, and invasion. S Figure 4 (A) Bar graph represents the percentage of viability of B20 treated macrophages. S Figure 5. VEGFR1-positive macrophages increase the effectiveness of anti-VEGF therapy.
Supplemental data from Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer
Authors: Skinner Heath D. , Giri Uma , Yang Liang P. , Kumar Manish , Liu Ying , Story Michael D. , Pickering Curtis R. , Byers Lauren A. , Williams Michelle D. , Wang Jing , Shen Li , Yoo Suk Y. , Fan You Hong , Molkentine David P. , Beadle Beth M. , Meyn Raymond E. , Myers Jeffrey N. , Heymach John V.
Published: April 2023

Supplemental data
Supplemental Table 1 from Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
Authors: Kim Joo Young , Brosnan-Cashman Jacqueline A. , An Soyeon , Kim Sung Joo , Song Ki-Byung , Kim Min-Sun , Kim Mi-Ju , Hwang Dae Wook , Meeker Alan K. , Yu Eunsil , Kim Song Cheol , Hruban Ralph H. , Heaphy Christopher M. , Hong Seung-Mo
Published: April 2023

Correlation between ALT status and ATRX and DAXX protein expression.
Supplementary Tables S1-S5 from Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma
Authors: Tranchant Robin , Quetel Lisa , Tallet Anne , Meiller Clement , Renier Annie , de Koning Leanne , de Reynies Aurelien , Le Pimpec-Barthes Francoise , Zucman-Rossi Jessica , Jaurand Marie-Claude , Jean Didier
Published: April 2023

This file contains supplementary tables S1- S5. Table S1: siRNA and TaqMan probes; Table S2: Primers used for LATS2 gene sequencing; Table S3: Differential phosphorylation level between C2LN MPM subgroup and other MPM; Table S4: LATS2 mutations in MPM; Table S5: Differential gene expression between C2LN MPM subgroup and other MPM.
Legends of Supplementary Figures from Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma
Authors: Tranchant Robin , Quetel Lisa , Tallet Anne , Meiller Clement , Renier Annie , de Koning Leanne , de Reynies Aurelien , Le Pimpec-Barthes Francoise , Zucman-Rossi Jessica , Jaurand Marie-Claude , Jean Didier
Published: April 2023

This file contains the legends for supplementary Figures S1-S7.
Figure Legend from Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma
Authors: Feldmeyer Laurence , Hudgens Courtney W. , Ray-Lyons Genevieve , Nagarajan Priyadharsini , Aung Phyu P. , Curry Jonathan L. , Torres-Cabala Carlos A. , Mino Barbara , Rodriguez-Canales Jaime , Reuben Alexandre , Chen Pei-Ling , Ko Jennifer S. , Billings Steven D. , Bassett Roland L. , Wistuba Ignacio I. , Cooper Zachary A. , Prieto Victor G. , Wargo Jennifer A. , Tetzlaff Michael T.
Published: April 2023

Figure Legend
Supplemental Table 2 from AMPK–ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells
Authors: Jang Ji Eun , Eom Ju-In , Jeung Hoi-Kyung , Cheong June-Won , Lee Jung Yeon , Kim Jin Seok , Min Yoo Hong
Published: April 2023

Patient characteristics according to JQ1 sensitivity in primary acute myeloid leukemia blasts
Supplementary data from Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer
Authors: Rosenthal Eben L. , Moore Lindsay S. , Tipirneni Kiranya , de Boer Esther , Stevens Todd M. , Hartman Yolanda E. , Carroll William R. , Zinn Kurt R. , Warram Jason M.
Published: April 2023

Supplementary data
Supplemental Table 1 from AMPK–ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells
Authors: Jang Ji Eun , Eom Ju-In , Jeung Hoi-Kyung , Cheong June-Won , Lee Jung Yeon , Kim Jin Seok , Min Yoo Hong
Published: April 2023

Effects of JQ1 on phenotypes and apoptosis of primary acute myeloid leukemia stem cells from 13 patietns
Supplementary materials, methods and tables from Downregulation of SAFB Sustains the NF-κB Pathway by Targeting TAK1 during the Progression of Colorectal Cancer
Authors: Jiao Hong-Li , Ye Ya-Ping , Yang Run-Wei , Sun Hui-Ying , Wang Shu-Yang , Wang Yong-Xia , Xiao Zhi-Yuan , He Liu-Qing , Cai Juan-Juan , Wei Wen-Ting , Chen Yan-Ru , Gu Chun-Cai , Cai Yue-Long , Hu Yun-Teng , Lai Qiu-Hua , Qiu Jun-Feng , Liang Li , Cao Guang-Wen , Liao Wen-Ting , Ding Yan-Qing
Published: April 2023

Supplementary materials, methods and tables
Figure S5 from Downregulation of SAFB Sustains the NF-κB Pathway by Targeting TAK1 during the Progression of Colorectal Cancer
Authors: Jiao Hong-Li , Ye Ya-Ping , Yang Run-Wei , Sun Hui-Ying , Wang Shu-Yang , Wang Yong-Xia , Xiao Zhi-Yuan , He Liu-Qing , Cai Juan-Juan , Wei Wen-Ting , Chen Yan-Ru , Gu Chun-Cai , Cai Yue-Long , Hu Yun-Teng , Lai Qiu-Hua , Qiu Jun-Feng , Liang Li , Cao Guang-Wen , Liao Wen-Ting , Ding Yan-Qing
Published: April 2023

Figure S5 shows that up-regulation of SAFB inhibited metastasis and angiogenesis in CRC through the SAFB-TAK1-NF-κB axis.
Supplementary Figure S1 Legend from Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials
Authors: Coleman C. Norman , Higgins Geoff S. , Brown J. Martin , Baumann Michael , Kirsch David G. , Willers Henning , Prasanna Pataje G.S. , Dewhirst Mark W. , Bernhard Eric J. , Ahmed Mansoor M.
Published: April 2023

Supplementary Figure S1 Legend from Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials
Figure S3 from Downregulation of SAFB Sustains the NF-κB Pathway by Targeting TAK1 during the Progression of Colorectal Cancer
Authors: Jiao Hong-Li , Ye Ya-Ping , Yang Run-Wei , Sun Hui-Ying , Wang Shu-Yang , Wang Yong-Xia , Xiao Zhi-Yuan , He Liu-Qing , Cai Juan-Juan , Wei Wen-Ting , Chen Yan-Ru , Gu Chun-Cai , Cai Yue-Long , Hu Yun-Teng , Lai Qiu-Hua , Qiu Jun-Feng , Liang Li , Cao Guang-Wen , Liao Wen-Ting , Ding Yan-Qing
Published: April 2023

Figure S3 shows that down-regulation of SAFB enhanced the activity of NF-κB signaling pathway by relieving transcription repression against TAK1
Supplementary Table S4 from Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts
Authors: Ivry Sam L. , Sharib Jeremy M. , Dominguez Dana A. , Roy Nilotpal , Hatcher Stacy E. , Yip-Schneider Michele T. , Schmidt C. Max , Brand Randall E. , Park Walter G. , Hebrok Matthias , Kim Grace E. , O'Donoghue Anthony J. , Kirkwood Kimberly S. , Craik Charles S.
Published: April 2023

Cathepsin E and gastricsin staining in cyst tissue.